Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3 study related to its AEZS-130 drug for treating adult growth hormone deficiency. The company now plans to consult with the FDA regarding the submission of a new drug application (NDA).
Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3...
From other sites
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
at CNBC.com (Mar 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs